Key points are not available for this paper at this time.
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTLessons Learned from Marketed and Investigational ProdrugsPeter Ettmayer, Gordon L. Amidon, Bernd Clement, and Bernard TestaView Author Information Novartis Institute for BioMedical Research, Brunnerstrasse 59, A-1235 Vienna, Austria, College of Pharmacy, The University of Michigan, Ann Arbor, Michigan 48109-1065, Pharmaceutical Institute, University of Kiel, D-24118 Kiel, Germany, and Department of Pharmacy, University Hospital Centre (CHUV), CH-1011 Lausanne, Switzerland Cite this: J. Med. Chem. 2004, 47, 10, 2393–2404Publication Date (Web):April 13, 2004Publication History Received7 August 2003Published online13 April 2004Published inissue 1 May 2004https://doi.org/10.1021/jm0303812Copyright © 2004 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views6980Altmetric-Citations282LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit Read OnlinePDF (231 KB) Get e-AlertsSUBJECTS:Cells,Metabolism,Peptides and proteins,Pharmaceuticals,Targeting Get e-Alerts
Ettmayer et al. (Tue,) studied this question.